Shares of Summit Therapeutics Inc. (NASDAQ:SMMT – Get Free Report) gapped up prior to trading on Monday . The stock had previously closed at $10.78, but opened at $11.25. Summit Therapeutics shares last traded at $10.95, with a volume of 197,405 shares traded.
Wall Street Analysts Forecast Growth
A number of research analysts have weighed in on SMMT shares. HC Wainwright began coverage on Summit Therapeutics in a research note on Monday. They set a “buy” rating and a $16.00 price target on the stock. Stifel Nicolaus increased their target price on Summit Therapeutics from $8.00 to $14.00 and gave the stock a “buy” rating in a research report on Monday, June 3rd. Finally, Citigroup lifted their price target on Summit Therapeutics from $7.00 to $13.00 and gave the company a “buy” rating in a report on Friday, May 31st.
Read Our Latest Stock Report on SMMT
Summit Therapeutics Price Performance
Institutional Inflows and Outflows
Hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. lifted its stake in shares of Summit Therapeutics by 3.6% during the first quarter. Vanguard Group Inc. now owns 7,269,243 shares of the company’s stock worth $30,095,000 after purchasing an additional 254,261 shares in the last quarter. TD Asset Management Inc purchased a new stake in shares of Summit Therapeutics during the 2nd quarter valued at about $2,081,000. China Universal Asset Management Co. Ltd. lifted its position in Summit Therapeutics by 66.3% during the 1st quarter. China Universal Asset Management Co. Ltd. now owns 134,845 shares of the company’s stock worth $558,000 after acquiring an additional 53,774 shares in the last quarter. Hoylecohen LLC boosted its holdings in Summit Therapeutics by 2.4% in the 2nd quarter. Hoylecohen LLC now owns 86,408 shares of the company’s stock worth $674,000 after acquiring an additional 2,000 shares during the period. Finally, Aristides Capital LLC purchased a new position in shares of Summit Therapeutics in the fourth quarter valued at $210,000. Hedge funds and other institutional investors own 4.61% of the company’s stock.
About Summit Therapeutics
Summit Therapeutics Inc, a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections.
See Also
- Five stocks we like better than Summit Therapeutics
- 5 discounted opportunities for dividend growth investors
- Monday.com’s Stock Results Will Brighten Any Investor’s Week
- ESG Stocks, What Investors Should Know
- 3 Must-Watch Stocks After a Bullish Goldman Sachs Recommendation
- How Can Investors Benefit From After-Hours Trading
- It’s Time to Take a Second Look at Take-Two Interactive Stock
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.